Obesity management needs medications on PBS: RACGP The college’s new obesity position statement calls for extra funding to treat the complex condition and for care to be made affordable for more patients.
Wegovy approved for cutting cardiovascular disease risk The TGA has approved semaglutide (sold as Wegovy) as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in overweight and obese adults.
World experts urge overhaul of obesity definition The Global Commission on Clinical Obesity says diagnosis must change, setting out new criteria, categories, and calling on doctors to go ‘beyond BMI’.
Mounjaro expanded to include weight management The TGA has approved tirzepatide for the treatment of overweight and obesity for those with comorbidities, via private prescription.
Study links semaglutide and suicidal ideation risk There are calls for urgent investigation into its impact on mental health, but GPs are urging caution when interpreting the research.
List of dementia risk factors grows The addition of untreated vision loss and high LDL cholesterol have bumped up the number of modifiable risk factors to 14.
Wegovy launches in Australia The manufacturer assured GPs supply planning has been its priority amid critical Ozempic shortages, but concerns remain over Wegovy’s availability.
Replica Ozempic and Mounjaro to be banned The Government has removed a loophole allowing the mass production of the compounded drugs amid growing patient safety concerns.
Sydney home raided after Ozempic scam The TGA is urging GPs ‘exercise deep caution’ after doctors were faxed ads promoting allegedly illegally compounded semaglutide.
‘Absolutely tiny’ Federal obesity funding challenged Questions have been raised about why no weight loss drugs are on the PBS, as research highlights the lack of funding for obesity prevention.